Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients

Journal of Endocrinological Investigation

Volumn 31, Issue 9, 2008, Pages 745-749

  Sieminska, Lusiem ^a   Niedziolka, D ^a   Pillich, A ^a   Kos Kudla, B ^a   Marek, B ^a   Nowak, M ^a   Borgiel Marek, H ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adiponectin; Graves' disease; Hyperthyroidism; Ophthalmopathy; Resistin

Indexed keywords

ADIPONECTIN; RESISTIN; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

EID: 57349126293     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349251     Document Type: Article

References (31)

1. Yu H, Yang Y, Zhang MX, et al. Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects. Nutr Metab (Lond) 2006, 3: 13.
2. Saito T, Kawano T, Saito T, et al. Elevation of serum adiponectin levels in Basedow disease. Metabolism 2005, 5: 146l-6.
3. Yaturu S, Prado S, Grimes SR. Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J Cell Biochem 2004, 93: 491-6.
4. Altinova AE, Törüner FB, Aktürk M, et al. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol (Oxf) 2006, 65: 530-5.
5. Santini F, Marsili A, Mammoli C, et al. Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions. J Endocrinol Invest 2004, 27: RC5-7.
6. Iglesias P, Alvarez Fidalgo P, Codoceo R, Díez JJ. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2003, 59: 621-9.
7. Pontikides N, Krassas GE. Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid 2007, 17: 421-31.
8. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002, 290: 1084-9.
9. Fernández-Real JM, López-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003, 88: 2714-8.
10. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004, 255: 439-47.
11. Nogueiras R, Gualillo O, Caminos JE, Casanueva FF, Diéguez C. Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 2003, 11: 408-14.
12. Krassas GE, Pontikides N, Loustis K, Koliakos G, Constantinidis T, Panidis D. Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition. Eur J Endocrinol 2005, 153: 217-21.
13. Harrison LC, Leedman PJ. The thyroid stimulating hormone receptor in human disease. Clin Biochem 1990, 23: 43-8.
14. Mysliwiec J, Kretowski A, Topolska J, et al. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids. Horm Metab Res 2001, 33: 739-43.
15. Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000, 143: 197-202.
16. Lappas M, Permezel M, Rice GE. Leptin and adiponectin stimulate the release of pro-inflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptorgamma and extracellularly regulated kinase 1/2. Endocrinology 2005, 146: 3334-42.
17. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6: 772-83.
18. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65: 1198-201.
19. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12: 100-5.
20. Imagawa A, Funahashi T, Nakamura T, et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002, 25: 1665-6.
21. Shalev A, Patterson NB, Hirshberg Rother KI, Harlan DM. Resistin serum levels in type 1 diabetes pre- and post-islet transplantation. Metabolism 2004, 53: 403-4.
22. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 2003, 30: 369-80.
23. Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2004, 89: 930-5.
24. Kumar S, Leontovich A, Coenen MJ, Bahn RS. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab 2005, 90: 4730-5.
25. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997, 47: 9-14.
26. Endo T, Ohta K, Haraguchi K, Onaya T. Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells. J Biol Chem 1995, 270: 10833-7.
27. Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases. Clin Exp Immunol 2005, 141: 388-97.
28. Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-gamma-inducible alphachemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006, 91: 614-20.
29. Feldon SE, O'loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce adipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 2006, 169: 1183-93.
30. Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004, 145: 367-83.
31. Sennello JA, Fayad R, Morris AM, et al. Regulation of T-cell mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005, 146: 2157-64.